Trinity Biotech Gets FDA Clearance for Preeclampsia Test
Ticker: TRIB · Form: 6-K · Filed: Aug 15, 2025 · CIK: 888721
| Field | Detail |
|---|---|
| Company | Trinity Biotech PLC (TRIB) |
| Form Type | 6-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, diagnostic-test, medical-device
TL;DR
Trinity Biotech snagged FDA approval for its preeclampsia test, PreClara™.
AI Summary
Trinity Biotech PLC announced on August 14, 2025, that it received FDA clearance for its PreClara™ preeclampsia testing service. This regulatory approval allows the company to proceed with offering this diagnostic service.
Why It Matters
FDA clearance for the PreClara™ test signifies a significant step for Trinity Biotech, potentially expanding its diagnostic offerings and impacting patient care for preeclampsia.
Risk Assessment
Risk Level: low — The filing is a routine 6-K report announcing regulatory approval, with no immediate financial or operational risks indicated.
Key Players & Entities
- TRINITY BIOTECH PLC (company) — Registrant
- PreClara™ (product) — FDA-Cleared testing service
- August 14, 2025 (date) — Date of press release
- FDA (organization) — Regulatory body
FAQ
What is the specific name of the FDA-cleared testing service?
The FDA-cleared testing service is named PreClara™.
On what date was the announcement of the FDA clearance made?
The announcement was made on August 14, 2025.
What type of condition does the PreClara™ test address?
The PreClara™ test addresses preeclampsia.
Which regulatory body granted the clearance for the PreClara™ test?
The U.S. Food and Drug Administration (FDA) granted the clearance.
In which filing is this press release being incorporated by reference?
This press release is being incorporated by reference into Trinity Biotech PLC's Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).
Filing Stats: 205 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-08-15 10:24:13
Filing Documents
- zk2533668.htm (6-K) — 11KB
- exhibit_99-1.htm (EX-99.1) — 14KB
- image00001.jpg (GRAPHIC) — 90KB
- 0001178913-25-002951.txt ( ) — 151KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/ John Gillard John Gillard Chief Executive Officer Date: August 14, 2025